-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alisertib in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alisertib in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in Recurrent Head And Neck...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target MAGE-A1 For Multiple Myeloma in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target MAGE-A1 For Multiple Myeloma in Refractory Multiple Myeloma Drug Details: Gene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venadaparib in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venadaparib in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venadaparib in Gastroesophageal (GE) Junction Carcinomas Drug Details: IDX-1197...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Metacavir in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Metacavir in Hepatitis B report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volrustomig in Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Renal Cell Carcinoma Drug Details: MEDI-5752 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LYS-006 in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYS-006 in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYS-006 in Hidradenitis Suppurativa Drug Details: LYS-006 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Acute Myeloblastic Leukemia in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Cellular Immunotherapy For Acute Myeloblastic Leukemia in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details:Cellular...
-
Company Profile
MediGene AG – Company Profile
MediGene AG (MediGene) is a biotechnology company which develops innovative immunotherapies to treat cancer with candidates in clinical and pre-clinical development. It focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects; and kills tumor cells and T-cell-specific monoclonal antibodies (TAB’s), for isolation of antibodies for monitoring and tracking of TCR-Ts. The company has operational presence in the US and Europe. Medigene is headquartered...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...